Impact of BCG Therapy Shortage on the Management of High-Risk NMIBC

Trinity Bivalacqua, MD, PhD and Mark Tyson, MD, MPH discuss the current shortage of BCG therapy and how that has impacted clinical practice management.

EP: 1.Prevalence and Staging of Newly Diagnosed Bladder Cancer

Now Viewing

EP: 2.Impact of BCG Therapy Shortage on the Management of High-Risk NMIBC

EP: 3.Recurrence and BCG Resistance in High-Risk NMIBC

EP: 4.Therapies Beyond BCG: FDA-Approved and Emerging Options

EP: 5.Cretostimogene, Grenadenorepvec, and Pembrolizumab for BCG-Unresponsive NMIBC: Overview of ASCO 2024 Data

EP: 6.CORE-001 Trial Participation and Eligibility Criteria

EP: 7.Comparing Cretostimogene and BCG Administration Methods

EP: 8.Results of the CORE-001 Trial: 24-Month Complete Response Rate and Duration of Response

EP: 9.Safety Outcomes and Duration of Response in Combination Therapy vs. Monotherapy for BCG UR CIS +/- Papillary Disease

EP: 10.Evaluating the Benefits of Cretostimogene Plus Pembrolizumab for BCG-Unresponsive NMIBC Management

EP: 11.Evaluating Cretostimogene: BOND-003 and PIVOT-006 Trial Results

EP: 12.Managing BCG-Unresponsive NMIBC: Cretostimogene Monotherapy vs. Combination Therapy

Video content above is prompted by the following:

• Can you describe the current shortage of bacillus Calmette-Guerin, or BCG, therapy; how has this has impacted your clinical practice and management of high-risk NMIBC?

Recent Videos